iwona Radziejewska

Dr. iwona Radziejewska

Department of Medical Chemistry, Medical University of Białystok
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Advances in Medical Sciences
Verified
Journal Article
Closed access
EGEwa Gindzienska-Sieskiewicz
Ewa Gindzienska-Sieskiewicz
IRiwona Radziejewska
iwona Radziejewska
IDIzabela Domysławska
Izabela Domysławska
PKPiotr Adrian Klimiuk
Piotr Adrian Klimiuk
ASAgnieszka Sulik
Agnieszka Sulik
SSStanisław Sierakowski
Stanisław Sierakowski

15 July 2021 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
KSKatarzyna Supruniuk
Katarzyna Supruniuk
IRiwona Radziejewska
iwona Radziejewska
Mucin 1 (MUC1) is a membrane‑bound, highly glycosylated protein that is overexpressed in all stages of malignant transformation. Overexpression of MUC1 together with loss of polarization and hypoglycosylation are associated with resistance to apoptosis, which is the process that results in efficient removal of damaged cells. Inhibition of the apoptotic process is responsible for tumor development, tumor progression and drug resistance. MUC1 is considered as an oncogenic molecule that is involved in various signaling pathways responsible for the regulation of apoptosis. Based on this, the aim of the present study was to discuss the involvement of MUC1 in the divergent mechanisms regulating programmed cell death.

1 November 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
IRiwona Radziejewska
iwona Radziejewska
KSKatarzyna Supruniuk
Katarzyna Supruniuk
JNJ. Nazaruk
J. Nazaruk
EKE. Karna
E. Karna
BPB. Popławska
B. Popławska
AGA. Galicka
A. Galicka

5 August 2014 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
MBMałgorzata Borzym-Kluczyk
Małgorzata Borzym-Kluczyk
IRiwona Radziejewska
iwona Radziejewska
Marzanna Cechowska-PaskoMarzanna Cechowska-Pasko
Marzanna Cechowska-Pasko

Verified
Journal Article
Open access
PDF file
IRiwona Radziejewska
iwona Radziejewska
KSKatarzyna Supruniuk
Katarzyna Supruniuk
Michał TomczykMichał Tomczyk
Michał Tomczyk
WIWiktoria Maria Izdebska
Wiktoria Maria Izdebska
MBMałgorzata Borzym-Kluczyk
Małgorzata Borzym-Kluczyk
AGAnna Galicka
Anna Galicka
Abnormal glycosylation of cancer cells is considered a key factor of carcinogenesis related to growth, proliferation, migration and invasion of tumor cells. Many plant-based polyphenolic compounds reveal potential anti-cancer properties effecting cellular signaling systems. Herein, we assessed the effects of phenolic acid, p-coumaric acid and flavonoids such as kaempferol, astragalin or tiliroside on expression of selected cancer-related glycoforms and enzymes involved in their formation in AGS gastric cancer cells. The cells were treated with 80 and 160 µM of the compounds. RT-PCR, Western blotting and ELISA tests were performed to determine the influence of polyphenolics on analyzed factors. All the examined compounds inhibited the expression of MUC1, ST6GalNAcT2 and FUT4 mRNAs. C1GalT1, St3Gal-IV and FUT4 proteins as well as MUC1 domain, Tn and sialyl T antigen detected in cell lysates were also lowered. Both concentrations of kaempferol, astragalin and tiliroside also suppressed ppGalNAcT2 and C1GalT1 mRNAs. MUC1 cytoplasmic domain, sialyl Tn, T antigens in cell lysates and sialyl T in culture medium were inhibited only by kaempferol and tiliroside. Nuclear factor NF-κB mRNA expression decreased after treatment with both concentrations of kaempferol, astragalin and tiliroside. NF-κB protein expression was inhibited by kaempferol and tiliroside. The results indicate the rationality of application of examined polyphenolics as potential preventive agents against gastric cancer development.

1 July 2021 in European Journal of Pharmacology
Verified
Journal Article
Open access
IRiwona Radziejewska
iwona Radziejewska
KSKatarzyna Supruniuk
Katarzyna Supruniuk
ABAnna Bielawska
Anna Bielawska
MUC1 seems to be promising target in cancer cells due to its abundant and specifically altered expression as well as differential distribution pattern relative to normal tissues. Rosmarinic acid (RA) is a natural, polyphenolic compound with pharmacological activities, including anti-cancer. Herein, we aim to explore the effect of combined action of anti-MUC1 and RA on selected cancer-related factors in AGS gastric cancer cells. Cancer cells were treated with 100, 200 μM rosmarinic acid, 5 μg/ml anti-MUC1 and acid together with antibody. Western blotting, ELISA and RT-PCR were used to assess the expression of MUC1, selected sugar antigens, enzymes participating in protein glycosylation, Gal-3, p53, pro- and anti-apoptotic factors, and caspases-3,-8,-9 in cancer cells. MUC1 mRNA was significantly suppressed by combined action of anti-MUC1 and RA. Such treatment markedly inhibited expression of cancer-related Tn, T, sialyl Tn, sialyl T, and fucosylated sugar antigens as well as mRNA expression of enzymes participating in their formation: ppGalNAcT2, C1GalT1, ST6GalNAcT2, ST3GalT1 and FUT4. C1GalT1 was suppressed also on protein level. Gal-3, factor likely participating in metastasis, was significantly suppressed on mRNA level by RA administrated with anti-MUC1. Pro-apoptotic Bax protein and Bad mRNA were significantly induced, and anti-apoptotic Bcl-2 mRNA expression was inhibited by such treatment. Combined action of mAb and RA markedly increased caspase-9 mRNA expression. Results of the study indicate that combined action of anti-MUC1 and RA is more effective than monotherapy in relation to examined cancer related factors. Such treatment can be considered as new, promising strategy in gastric cancer therapy.